Baseline and post-treatment characteristics of the studied groups.

*
p≤0.05 vs pre-treatment vehicle; †p≤0.05 vs pre-treatment sildenafil; ‡p≤0.05 vs pre-treatment riociguat; §p≤0.05 vs post-treatment vehicle; ¶p≤0.05 vs post-treatment sildenafil.

Note. MPI, myocardial performance index; ‘notch’ duration, pulmonary artery flow mid-systolic notch duration; PAAT, pulmonary artery acceleration time; RVID, right ventricular internal diameter, RVWT, right ventricular wall thickness, TAPSE, tricuspid annular plane systolic excursion.

* p≤0.05 较治疗前溶剂对照组有统计学差异；† p≤0.05 较治疗前西地那非（sildenafil）组有统计学差异；‡ p≤0.05 较治疗前利奥西呱（riociguat）组有统计学差异；§ p≤0.05 较治疗后溶剂对照组有统计学差异；¶ p≤0.05 较治疗后西地那非组有统计学差异。

注：MPI即心肌功能指数（myocardial performance index）；‘切迹’持续时间指肺动脉血流收缩中期切迹持续时间；PAAT即肺动脉加速时间（pulmonary artery acceleration time）；RVID即右心室内径（right ventricular internal diameter），RVWT即右心室壁厚度（right ventricular wall thickness），TAPSE即三尖瓣环平面收缩期位移（tricuspid annular plane systolic excursion）。